Gaza ambulance fleet down to a third, Palestinian Red Crescent says
GENEVA, May 22 (Reuters) - The head of the Palestinian Red Crescent said on Thursday its operations in Gaza may stop within days in the absence of fresh supplies and its ambulance fleet was running at only a third of capacity due to fuel shortages.
Flour and other aid began reaching some of Gaza's most vulnerable areas on Thursday after Israel let some trucks through, but nowhere near enough to make up for shortages caused by an 11-week Israeli blockade, Palestinian officials said.
Israel said it let in 100 trucks carrying baby food and medical equipment on Wednesday, two days after announcing its first relaxation of the blockade under mounting international pressure amid warnings of starvation in Gaza.
Asked how long his organisation could continue operating in Gaza, Palestine Red Crescent Society President Younis Al-Khatib told reporters in Geneva: "It's a matter of time. It could be days.
"We are running out of fuel. The capacity of ambulances we work with now is one third," he added, saying its gasoline-powered ambulances had already halted but it had some that were running on solar power provided by the United Nations.
The PRCS is part of the world's largest humanitarian network, the International Federation of Red Cross and Red Crescent Societies, and provides medical care in the Gaza Strip and the Israeli-occupied West Bank.
Al-Khatib criticised the small amount of aid Israel has allowed into Gaza so far, warning of the risk of mob attacks.
"I think that is an invitation for killing. These people are starving," he said.
Israel, at war with Gaza's dominant militant group Hamas since October 2023, has repeatedly defended its controls on aid in the enclave, saying there is enough food there and denying accusations of causing starvation.
He added his voice to criticism of a U.S.-backed organisation that aims to start work in Gaza by the end of May overseeing a new model of aid distribution. "It's not up for discussion. No, no, no," he said.
"The world should not give up on the system as we know it."
The U.S.-backed Gaza Humanitarian Foundation intends to work with private U.S. security and logistics firms to provide aid to 300,000 people from distribution hubs in Gaza's south. Gaza's total population is 2.3 million, most of it displaced.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
6 hours ago
- The Independent
Critically ill patients with sepsis more likely to survive when given statins
Research indicates that critically ill sepsis patients who receive statins may have a higher chance of survival. A study of 6,000 sepsis patients given statins showed 14.3 per cent died within 28 days, compared to 23.4 per cent of 6,000 patients who did not receive statins, equating to a 39% reduced risk of death. The study, conducted using data from a hospital in Israel between 2008 and 2019, also found lower mortality rates in intensive care and overall hospital stays for statin users. Dr. Caifeng Li, the study's corresponding author, suggested that statins may offer a protective effect and improve outcomes for sepsis patients. Dr. Ron Daniels, founder and chief executive of the UK Sepsis Trust, supports calls for larger trials to confirm the findings, noting the potential survival benefit from the anti-inflammatory properties of statins.
The Independent
7 hours ago
- The Independent
This common prescription drug could reduce deaths by sepsis, study finds
Critically ill patients with sepsis who are given statins may be more likely to survive, new research suggests. Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients. The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year. UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
BreakingNews.ie
7 hours ago
- BreakingNews.ie
Statins can reduce sepsis deaths, study suggests
People who are critically ill with sepsis may be more likely to survive if they are given statins, a new study suggests. Researchers wanted to explore whether the cholesterol-busting drugs may bring additional benefits for patients. Advertisement The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. Advertisement The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Advertisement Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In Ireland, about 12,000 people are affected by sepsis every year, according to the HSE. Sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. Advertisement But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Advertisement Ireland Sepsis: Doctors launch awareness campaign about le... Read More Commenting on the study, Dr Ron Daniels, founder and chief executive of the Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
